DNA Repair Biomarkers Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer

被引:45
|
作者
Alexander, Brian M. [1 ]
Wang, Xiao Zhe [2 ,3 ]
Niemierko, Andrzej
Weaver, David T. [2 ,3 ]
Mak, Raymond H.
Roof, Kevin S. [6 ]
Fidias, Panagiotis [4 ]
Wain, John [5 ]
Choi, Noah C.
机构
[1] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA
[2] On Q Ity Inc, Waltham, MA USA
[3] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[5] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA
[6] SE Radiat Oncol, Charlotte, NC USA
关键词
Biomarkers; Chemoradiotherapy; DNA repair; Esophageal cancer; SQUAMOUS-CELL CARCINOMA; POOR-PROGNOSIS; CHEMOTHERAPY; EXPRESSION; CHEMORADIATION; DEFICIENCY; CISPLATIN; BENEFITS; HMLH1;
D O I
10.1016/j.ijrobp.2011.05.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The addition of neoadjuvant chemoradiotherapy prior to surgical resection for esophageal cancer has improved clinical outcomes in some trials. Pathologic complete response (pCR) following neoadjuvant therapy is associated with better clinical outcome in these patients, but only 22% to 40% of patients achieve pCR. Because both chemotherapy and radiotherapy act by inducing DNA damage, we analyzed proteins selected from multiple DNA repair pathways, using quantitative immunohistochemistry coupled with a digital pathology platform, as possible biomarkers of treatment response and clinical outcome. Methods and Materials: We identified 79 patients diagnosed with esophageal cancer between October 1994 and September 2002, with biopsy tissue available, who underwent neoadjuvant chemoradiotherapy prior to surgery at the Massachusetts General Hospital and used their archived, formalin-fixed, paraffin-embedded biopsy samples to create tissue microarrays (TMA). TMA sections were stained using antibodies against proteins in various DNA repair pathways including XPF, FANCD2, PAR, MLH1, PARP1, and phosphorylated MAPKAP kinase 2 (pMK2). Stained TMA slides were evaluated using machine-based image analysis, and scoring incorporated both the intensity and the quantity of positive tumor nuclei. Biomarker scores and clinical data were assessed for correlations with clinical outcome. Results: Higher scores for MLH1 (p = 0.018) and lower scores for FANCD2 (p = 0.037) were associated with pathologic response to neoadjuvant chemoradiation on multivariable analysis. Staining of MLH1, PARP1, XPF, and PAR was associated with recurrence-free survival, and staining of PARP1 and FANCD2 was associated with overall survival on multivariable analysis. Conclusions: DNA repair proteins analyzed by immunohistochemistry may be useful as predictive markers for response to neoadjuvant chemoradiotherapy in patients with esophageal cancer. These results are hypothesis generating and need confirmation in an independent data set. (C) 2012 Elsevier Inc.
引用
收藏
页码:164 / 171
页数:8
相关论文
共 50 条
  • [41] A comparison of two neoadjuvant chemoradiotherapy regimens for esophageal cancer
    Borggreve, A. S.
    Thomas, M.
    Moons, J.
    Van Hillegersberg, R.
    Van Rossum, P. S. N.
    Mook, S.
    Ruurda, J. P.
    Nafteux, P.
    Haustermans, K.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S83 - S83
  • [42] Clinical Factors to Predict the Response to Concurrent Chemoradiotherapy and Survival in Esophageal Cancer Patients
    Nam, Su Youn
    Jeon, Seong Woo
    Lee, Sang Jik
    Kwon, Yong Hwan
    Lee, Hyun Seok
    Kim, Sung Kook
    GUT AND LIVER, 2020, 14 (04) : 450 - 458
  • [43] Neoadjuvant chemoradiotherapy for operable esophageal cancer: Is paclitaxel necessary?
    Chino, J. P.
    Kelsey, C. R.
    Willett, C. G.
    Clough, R.
    Bendell, J. C.
    Hurwitz, H. I.
    D'Amico, T.
    Czito, B. G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S292 - S293
  • [44] Is Neoadjuvant Chemoradiotherapy Safe for Elderly Patients with Esophageal Cancer?
    Wu, Geena X.
    Ituarte, Philip H. G.
    Chao, Joseph
    Chen, Yi-Jen
    Raz, Dan J.
    Trisal, Vijay
    Kim, Jae Y.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 221 (04) : S150 - S151
  • [45] Neoadjuvant chemoradiotherapy for esophageal cancer - a single institution experience
    Ermenc, A. Secerov
    Anderluh, F.
    Peressutti, A. Jeromen
    Velenik, V.
    Oblak, I.
    Korosec, P.
    Hadzic, J. But
    Pulko, N.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1095 - S1095
  • [46] Nomogram for Predicting Pathologic Response Following Neoadjuvant Chemotherapy or Chemoradiotherapy in Patients with Esophageal Cancer
    Ribeiro Jr, Ulysses
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (04) : 1945 - 1947
  • [47] Osteosarcopenia as a Predictor of Histopathologic Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer: a Retrospective Cohort Study
    Hirase, Yuki
    Sasaki, Ken
    Tsuruda, Yusuke
    Shimonosono, Masataka
    Uchikado, Yasuto
    Matsushita, Daisuke
    Arigami, Takaaki
    Tada, Nobuhiro
    Baba, Kenji
    Kawasaki, Yota
    Ohtsuka, Takao
    LANGENBECKS ARCHIVES OF SURGERY, 2025, 410 (01)
  • [48] Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer
    Liu, Jing
    Yue, Jinbo
    Xing, Ligang
    Yu, Jinming
    FRONTIERS OF MEDICINE, 2013, 7 (02) : 172 - 179
  • [49] Neoadjuvant chemotherapy versus chemoradiotherapy for esophageal cancer: a tradeoff between dysphagia and pathologic response
    Lui, Natalie
    VIDEO-ASSISTED THORACIC SURGERY, 2018, 3
  • [50] Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer
    Kato, H
    Kuwano, H
    Nakajima, M
    Miyazaki, T
    Yoshikawa, M
    Masuda, N
    Fukuchi, M
    Manda, R
    Tsukada, K
    Oriuchi, N
    Endo, K
    AMERICAN JOURNAL OF SURGERY, 2002, 184 (03): : 279 - 283